Biopharma

Scientific Publications

Number Title Date of Creation
18 Clinical and biomarker analyses of a phase II study of intratumoral tavokinogene telseplasmid (pIL-12) plus pembrolizumab in stage III/IV melanoma patients predicted to not respond to anti-PD-1SITC 2017 2018. 09. 10
17 Intratumoral Administration Of A Multigene Construct By Electroporation Can Effectively Modulate Anti-Tumor Response In A Murine B16.f10 Model 2018. 09. 10
16 Clinical Immune Monitoring and Biomarker Data of TAVO Monotherapy Compared to TAVO with Pembrolizumab in Metastatic Melanoma Supports the Rationale for Combination Therapy 2018. 09. 10
15 Intratumoral Delivery of a P2A-linked Bicistronic IL-12 Construct Leads to High Intratumoral Expression and Systemic Anti-tumor Response 2018. 09. 10
14 Intratumoral Electroporation-Mediated IL-12 Gene Therapy can Enhance Tumor Immunogenicity 2018. 09. 10
13 Immune Monitoring Outcomes of Patients with Stage III/IV Melanoma Treated with a Combination of Pembrolizumab and Intratumoral Plasmid Interleukin 12 (pIL-12) 2018. 09. 10
12 Phase II Study of Intratumoral Plasmid Interleukin 12 (pIL-12) with Electroporation 2018. 09. 10
11 Intratumoral IL-12 Therapy in HNSCC 2018. 09. 10
10 A Novel Applicator for Endoscopic Gene Electro-Transfer 2018. 09. 10
9 Feedback Optimized Gene Electro-Transfer for Immunotherapy 2018. 09. 10
8 Priming response to anti-PD1/PDL1 blockade with intratumoral electroporation of plasmid IL-12 in advanced melanoma 2018. 09. 10
7 In vivoIntratumoral Electroporation of Gp96-Ig/Fc-OX40L Stimulates CD8+ T cell Cross Priming to Tumor-Specific Neoantigens 2018. 09. 10